-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SNw3RSnrscYTagPwgCJo2n3nfMBgV+YKUZ1cPfEr0zlX7wFuTSnmhIX1ZvJRxZgX INE2AlDWuXzHJMWuVDfCLw== 0001024739-99-000002.txt : 19990107 0001024739-99-000002.hdr.sgml : 19990107 ACCESSION NUMBER: 0001024739-99-000002 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19990106 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000880771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943116852 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: SEC FILE NUMBER: 005-43408 FILM NUMBER: 99501728 BUSINESS ADDRESS: STREET 1: 901 MARINERS ISLAND BLVD STREET 2: SUITE 315 CITY: SAN MATEO STATE: CA ZIP: 94404 BUSINESS PHONE: 6503583456 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: HALIFAX FUND LP CENTRAL INDEX KEY: 0001075674 STANDARD INDUSTRIAL CLASSIFICATION: [] FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: C/O THE PALLADIN GROUP INC STREET 2: 40 WEST 57TH STREET CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 2126980500 SC 13G 1 SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SciClone Pharmaceuticals, Inc. ------------------------------ (Name of Issuer) Common Stock, no par value ------------------------------ (Title of Class of Securities) 80862K104 -------------- (CUSIP Number) December 15, 1998 ------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ( ) Rule 13d-1(b) (x) Rule 13d-1(c) ( ) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act. (Page 1 of 6 Pages) CUSIP No. 80862K104 13G Page 2 of 6 Pages - -------------------------------------------------------------------------------- 1) NAME OF REPORTING PERSON Halifax Fund, L.P. - -------------------------------------------------------------------------------- 2) CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP (a) [ ] (b) [ ] - -------------------------------------------------------------------------------- 3) SEC USE ONLY - -------------------------------------------------------------------------------- 4) CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands - -------------------------------------------------------------------------------- 5) SOLE VOTING POWER 2,137,068 NUMBER OF ------------------------------------------------------------------ SHARES 6) SHARED VOTING POWER BENEFICIALLY 0 OWNED BY ------------------------------------------------------------------ EACH 7) SOLE DISPOSITIVE POWER REPORTING 2,137,068 PERSON WITH ------------------------------------------------------------------ 8) SHARED DISPOSITIVE POWER 0 - -------------------------------------------------------------------------------- 9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,137,068 - -------------------------------------------------------------------------------- 10) CHECK IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES [ ] - -------------------------------------------------------------------------------- 11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 9.9% - -------------------------------------------------------------------------------- 12) TYPE OF REPORTING PERSON: OO - -------------------------------------------------------------------------------- Item 1(a). Name of Issuer: - ---------- --------------- SciClone Pharmaceuticals, Inc. Item 1(b). Address of Issuer's Principal Executive Offices: - ---------- ------------------------------------------------ 901 Mariners Island Blvd Suite 315 San Mateo, California 94404 Item 2(a). Name of Person Filing: - ---------- ---------------------- Halifax Fund, L.P. Item 2(b). Address of Principal Business Office: - ---------- ------------------------------------- c/o The Palladin Group, L.P. 40 West 57th Street 15th Floor New York, NY 10019 Item 2(c). Citizenship: - ---------- ------------ Cayman Islands Item 2(d). Title of Class of Securities: - ---------- ----------------------------- Common Stock Item 2(d). CUSIP Number: - ---------- ------------- 80862K104 Page 3 of 6 Pages If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), Item 3. check whether the person filing is a: - ------- -------------------------------------------------------------- (a) [ ] Broker or dealer registered under Section 15 of the Exchange Act. (b) [ ] Bank as defined in Section 3(a)(6) of the Exchange Act. (c) [ ] Insurance company as defined in Section 3(a)(19) of the Exchange Act. (d) [ ] Investment company registered under Section 8 of the Investment Company Act. (e) [ ] An investment advisor in accordance with Rule 13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (i) [ ] A church plan that is excluded form the definition of an investment company under section 3(c)(14) of the Investment Company Act; (j) [ ] Group, in accordance with Rule 13d-1(b)1)(ii)(J). Item 4. Ownership. - ------- --------- (a) Amount Beneficially Owned: 2,137,068 (b) Percent of Class: 9.9% (c) Number of Shares to which such person has: (i) Sole power to vote or direct the vote: 2,137,068 (ii) Shared power to vote or direct the vote: 0 (iii) Sole power to dispose or to direct the deposition of: 2,137,068 (iv) Shared power to dispose or to direct the disposition of: 0 Page 4 of 6 Pages Item 5. Ownership of Five Percent or Less of a Class. - ------- --------------------------------------------- If this statement is being filed to report the fact that as of the date of the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ]. Ownership of More than Five Percent on Behalf of Item 6. Another Person - ------- ------------------------------------------------ Not Applicable. Identification and Classification of the Subsidiary Which acquired the Security Being Item 7. Reported on By the Parent Holding Company - ------- -------------------------------------------- Not Applicable. Identification and Classification of Members of Item 8. the Group. - ------- ----------------------------------------------- Not Applicable. Item 9. Notice of Dissolution of the Group. - ------- ----------------------------------- Not Applicable. Page 5 of 6 Pages Item 10. Certification. - -------- -------------- By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonably inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. January 6, 1999 ---------------------------------------- Date Halifax Fund, L.P. By: The Palladin Group, L.P. Attorney-in-fact By: Palladin Capital Management, L.L.C. General Partner /s/ Robert L. Chender ---------------------------------------- Signature Robert L. Chender Duly Authorized Signatory ---------------------------------------- Name/Title Page 6 of 6 Pages -----END PRIVACY-ENHANCED MESSAGE-----